Neurogene (NGNE) Competitors

Phibro Animal Health (NASDAQ:PAHC) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Do analysts prefer PAHC or NGNE?

Phibro Animal Health presently has a consensus target price of $20.00, indicating a potential downside of 13.12%. Neurogene has a consensus target price of $44.60, indicating a potential upside of 147.23%. Given Neurogene's stronger consensus rating and higher probable upside, analysts plainly believe Neurogene is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Neurogene	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Do insiders and institutionals have more ownership in PAHC or NGNE?

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 9.9% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor PAHC or NGNE?

In the previous week, Neurogene had 12 more articles in the media than Phibro Animal Health. MarketBeat recorded 19 mentions for Neurogene and 7 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.57 beat Neurogene's score of 0.34 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neurogene	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in PAHC or NGNE?

Phibro Animal Health received 286 more outperform votes than Neurogene when rated by MarketBeat users. However, 88.57% of users gave Neurogene an outperform vote while only 59.81% of users gave Phibro Animal Health an outperform vote.

Company	Underperform	Outperform
Phibro Animal Health	Outperform Votes 317 59.81%	Underperform Votes 213 40.19%
Neurogene	Outperform Votes 31 88.57%	Underperform Votes 4 11.43%

Which has more volatility and risk, PAHC or NGNE?

Phibro Animal Health has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Which has stronger earnings & valuation, PAHC or NGNE?

Phibro Animal Health has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.19B	0.78	$2.42M	$0.78	29.51
Neurogene	$925K	278.15	-$36.32M	-$4.35	-4.15

Is PAHC or NGNE more profitable?

Phibro Animal Health has a net margin of 1.75% compared to Neurogene's net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	1.75%	25.35%	6.21%
Neurogene	N/A	-32.81%	-27.96%

Summary

Phibro Animal Health beats Neurogene on 11 of the 18 factors compared between the two stocks.